UNSPSC 51401531: Nordazepam

This classification denotes a benzodiazepine with the molecular formula C15H11ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67220MCM01, chemically known as 7-chloro-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as nordazepam, which bears US NIH Compound Identifier 2997. European Medicines Agency schedules Nordazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09358MIG.

UNSPSC 51401531 Nordazepam is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent solicitations show the code is being applied broadly to multi-source generics, over-the-counter products, and naloxone—extending well beyond nordazepam specifically. State and local buyers under this code include county health departments and cooperative purchasing alliances serving multiple jurisdictions and state agencies. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the bid was due July 26, 2023, and required electronic submission through the county's e-Procurement Portal with all shipping included. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026, requiring manufacturers to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards.

Recent activity spans Florida and a multistate cooperative led by Minnesota covering Oregon and other participating jurisdictions. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative, reflecting state interest in alternative contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. Vendors pursuing this code face substantive compliance requirements, including E-Verify employment verification, drug-free workplace certification, comprehensive insurance coverage (commercial general liability, workers' compensation, and professional liability), FDA compliance, and supply chain security standards. The Minnesota cooperative procurement weighted price competitiveness at 75 percent of evaluation criteria, with administrative fees of 3 percent assessed on all contract purchases and performance penalties ranging from $200 to $1,500 per violation.